Molecular Cancer Therapeutics: 12 (6)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther June 1 2013 12 (6) 829-829;

Reviews

Reviews

Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma

Lisa Vincenz, Richard Jäger, Michael O'Dwyer and Afshin Samali

Mol Cancer Ther June 1 2013 12 (6) 831-843; DOI:10.1158/1535-7163.MCT-12-0782
Reviews

Cyclooxygenase-2, Epidermal Growth Factor Receptor, and Aromatase Signaling in Inflammation and Mesothelioma

Barbara Nuvoli and Rossella Galati

Mol Cancer Ther June 1 2013 12 (6) 844-852; DOI:10.1158/1535-7163.MCT-12-1103

Chemical Therapeutics

Chemical Therapeutics | AuthorChoice

Bcl-2/Bcl-x_L Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models

Nguyen Tan, Maureen Wong, Michelle A. Nannini, Rebecca Hong, Leslie B. Lee, Stephen Price, Karen Williams, Pierre Pascal Savy, Peng Yue, Deepak Sampath, Jeffrey Settleman, Wayne J. Fairbrother and Lisa D. Belmont

Mol Cancer Ther June 1 2013 12 (6) 853-864; DOI:10.1158/1535-7163.MCT-12-0949
Chemical Therapeutics

RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib

Ahrum Min, Seock-Ah Im, Young-Kwang Yoon, Sang-Hyun Song, Hyun-Jin Nam, Hyung-Seok Hur, Hwang-Phill Kim, Kyung-Hun Lee, Sae-Won Han, Do-Youn Oh, Tae-You Kim, Mark J. O'Connor, Woo-Ho Kim and Yung-Jue Bang

Mol Cancer Ther June 1 2013 12 (6) 865-877; DOI:10.1158/1535-7163.MCT-12-0950
Chemical Therapeutics

The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair

Yun Dai, Shuang Chen, Maciej Kmieciak, Liang Zhou, Hui Lin, Xin-Yan Pei and Steven Grant

Mol Cancer Ther June 1 2013 12 (6) 878-889; DOI:10.1158/1535-7163.MCT-12-0902
Chemical Therapeutics

The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth

Edward B. Garon, Richard S. Finn, Habib Hamidi, Judy Dering, Sharon Pitts, Naeimeh Kamranpour, Amrita J. Desai, Wylie Hosmer, Susan Ide, Emin Avsar, Michael Rugaard Jensen, Cornelia Quadt, Manway Liu, Steven M. Dubinett and Dennis J. Slamon

Mol Cancer Ther June 1 2013 12 (6) 890-900; DOI:10.1158/1535-7163.MCT-12-0998
Chemical Therapeutics

Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma

H. Eirik Haarberg, Kim H.T. Paraiso, Elizabeth Wood, Vito W. Rebecca, Vernon K. Sondak, John M. Koomen and Keiran S.M. Smalley

Mol Cancer Ther June 1 2013 12 (6) 901-912; DOI:10.1158/1535-7163.MCT-12-1003
Chemical Therapeutics

A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities

Yoshiko Awazu, Kazuhide Nakamura, Akio Mizutani, Yuichi Kakoi, Hidehisa Iwata, Seiji Yamasaki, Naoki Miyamoto, Shinichi Imamura, Hiroshi Miki and Akira Hori

Mol Cancer Ther June 1 2013 12 (6) 913-924; DOI:10.1158/1535-7163.MCT-12-1011
Chemical Therapeutics | AuthorChoice

Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion

Jing Wang, Natalie W. Pursell, Maria Elena S. Samson, Ruzanna Atoyan, Anna W. Ma, Abdelkader Selmi, Wanlu Xu, Xiong Cai, Maurizio Voi, Pierre Savagner and Cheng-Jung Lai

Mol Cancer Ther June 1 2013 12 (6) 925-936; DOI:10.1158/1535-7163.MCT-12-1045
Chemical Therapeutics

Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer

Shili Xu, Fedora Grande, Antonio Garofalo and Nouri Neamati

Mol Cancer Ther June 1 2013 12 (6) 937-949; DOI:10.1158/1535-7163.MCT-12-1082
Chemical Therapeutics

Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo

Hua Xie, Mee-Hyun Lee, Feng Zhu, Kanamata Reddy, Zunnan Huang, Dong Joon Kim, Yan Li, Cong Peng, Do Young Lim, Soouk Kang, Sung Keun Jung, Xiang Li, Haitao Li, Weiya Ma, Ronald A. Lubet, Jian Ding, Ann M. Bode and Zigang Dong

Mol Cancer Ther June 1 2013 12 (6) 950-958; DOI:10.1158/1535-7163.MCT-12-1241
Chemical Therapeutics

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

Michael A. Batey, Yan Zhao, Suzanne Kyle, Caroline Richardson, Andrew Slade, Niall M.B. Martin, Alan Lau, David R. Newell and Nicola J. Curtin

Mol Cancer Ther June 1 2013 12 (6) 959-967; DOI:10.1158/1535-7163.MCT-12-0707

Large Molecule Therapeutics

Large Molecule Therapeutics

Milatuzumab–SN-38 Conjugates for the Treatment of CD74⁺ Cancers

Serengulam V. Govindan, Thomas M. Cardillo, Robert M. Sharkey, Fatma Tat, David V. Gold and David M. Goldenberg

Mol Cancer Ther June 1 2013 12 (6) 968-978; DOI:10.1158/1535-7163.MCT-12-1170
Large Molecule Therapeutics | Free Article

Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu

Yu Cao, Khalid A. Mohamedali, John W. Marks, Lawrence H. Cheung, Walter N. Hittelman and Michael G. Rosenblum

Mol Cancer Ther June 1 2013 12 (6) 979-991; DOI:10.1158/1535-7163.MCT-13-0002

Cancer Therapeutics Insights

Cancer Therapeutics Insights

BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer

Bercin Kutluk Cenik, Katherine T. Ostapoff, David E. Gerber and Rolf A. Brekken

Mol Cancer Ther June 1 2013 12 (6) 992-1001; DOI:10.1158/1535-7163.MCT-12-0995
Cancer Therapeutics Insights

Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer

Maike Ihnen, Christine zu Eulenburg, Teodora Kolarova, Jing Wei Qi, Kanthinh Manivong, Meenal Chalukya, Judy Dering, Lee Anderson, Charles Ginther, Alexandra Meuter, Boris Winterhoff, Siân Jones, Victor E. Velculescu, Natarajan Venkatesan, Hong-Mei Rong, Sugandha Dandekar, Nitin Udar, Fritz Jänicke, Gerrit Los, Dennis J. Slamon and Gottfried E. Konecny

Mol Cancer Ther June 1 2013 12 (6) 1002-1015; DOI:10.1158/1535-7163.MCT-12-0813
Cancer Therapeutics Insights | AuthorChoice

Downregulation of Hepatoma-Derived Growth Factor Contributes to Retarded Lung Metastasis via Inhibition of Epithelial–Mesenchymal Transition by Systemic POMC Gene Delivery in Melanoma

Han-En Tsai, Guei-Sheung Liu, Mei-Lang Kung, Li-Feng Liu, Jian-Ching Wu, Chia-Hua Tang, Ching-Hui Huang, San-Cher Chen, Hing-Chung Lam, Chieh-Shan Wu and Ming-Hong Tai

Mol Cancer Ther June 1 2013 12 (6) 1016-1025; DOI:10.1158/1535-7163.MCT-12-0832
Cancer Therapeutics Insights

Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals

Xiaohai Wang, Soo Ok Lee, Shujie Xia, Qi Jiang, Jie Luo, Lei Li, Shuyuan Yeh and Chawnshang Chang

Mol Cancer Ther June 1 2013 12 (6) 1026-1037; DOI:10.1158/1535-7163.MCT-12-0895
Cancer Therapeutics Insights

Combining Hedgehog Signaling Inhibition with Focal Irradiation on Reduction of Pancreatic Cancer Metastasis

Dongsheng Gu, Hailan Liu, Gloria H. Su, Xiaoli Zhang, Helen Chin-Sinex, Helmut Hanenberg, Marc S. Mendonca, Harlan E. Shannon, E. Gabriela Chiorean and Jingwu Xie

Mol Cancer Ther June 1 2013 12 (6) 1038-1048; DOI:10.1158/1535-7163.MCT-12-1030
Cancer Therapeutics Insights

Hrk Mediates 2-Methoxyestradiol–Induced Mitochondrial Apoptotic Signaling in Prostate Cancer Cells

Inik Chang, Shahana Majid, Sharanjot Saini, Mohd S. Zaman, Soichiro Yamamura, Takeshi Chiyomaru, Varahram Shahryari, Shinichiro Fukuhara, Guoren Deng, Rajvir Dahiya and Yuichiro Tanaka

Mol Cancer Ther June 1 2013 12 (6) 1049-1059; DOI:10.1158/1535-7163.MCT-12-1187
Cancer Therapeutics Insights

SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ

Monica Brenca, Sabrina Rossi, Erica Lorenzetto, Elena Piccinin, Sara Piccinin, Francesca Maria Rossi, Alberto Giuliano, Angelo Paolo Dei Tos, Roberta Maestro and Piergiorgio Modena

Mol Cancer Ther June 1 2013 12 (6) 1060-1072; DOI:10.1158/1535-7163.MCT-13-0005
Cancer Therapeutics Insights

Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair

Kushtrim Kryeziu, Ute Jungwirth, Mir Alireza Hoda, Franziska Ferk, Siegfried Knasmüller, Claudia Karnthaler-Benbakka, Christian R. Kowol, Walter Berger and Petra Heffeter

Mol Cancer Ther June 1 2013 12 (6) 1073-1084; DOI:10.1158/1535-7163.MCT-13-0065
Cancer Therapeutics Insights

Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs

Stefania Stella, Elena Tirrò, Enrico Conte, Fabio Stagno, Francesco Di Raimondo, Livia Manzella and Paolo Vigneri

Mol Cancer Ther June 1 2013 12 (6) 1085-1098; DOI:10.1158/1535-7163.MCT-12-0550
Cancer Therapeutics Insights

Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP

Xuemei Xie, Chandra Bartholomeusz, Ahmed A. Ahmed, Anna Kazansky, Lixia Diao, Keith A. Baggerly, Gabriel N. Hortobagyi and Naoto T. Ueno

Mol Cancer Ther June 1 2013 12 (6) 1099-1111; DOI:10.1158/1535-7163.MCT-12-0737

Companion Diagnostics & Cancer Biomarkers

Companion Diagnostics & Cancer Biomarkers

Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease

Lai-Ping Zhong, Dong-Wang Zhu, William N. William Jr, Ying Liu, Jie Ma, Cheng-Zhe Yang, Xiao Yang, Li-Zhen Wang, Jiang Li, Jeffrey N. Myers, J. Jack Lee, Chen-Ping Zhang and Zhi-Yuan Zhang

Mol Cancer Ther June 1 2013 12 (6) 1112-1121; DOI:10.1158/1535-7163.MCT-12-1013
Companion Diagnostics & Cancer Biomarkers

HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors

Elicia Penuel, Congfen Li, Vaishali Parab, Luciana Burton, Kyra J. Cowan, Mark Merchant, Robert L. Yauch, Premal Patel, Amy Peterson, Garret M. Hampton, Mark R. Lackner and Priti S. Hegde

Mol Cancer Ther June 1 2013 12 (6) 1122-1130; DOI:10.1158/1535-7163.MCT-13-0015
Companion Diagnostics & Cancer Biomarkers

ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer

Rebekah L. Zinn, Eric E. Gardner, Luigi Marchionni, Sara C. Murphy, Irina Dobromilskaya, Christine L. Hann and Charles M. Rudin

Mol Cancer Ther June 1 2013 12 (6) 1131-1139; DOI:10.1158/1535-7163.MCT-12-0618

Tools and Technologies

Tools and Technologies

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model

Holly A.F. Stessman, Linda B. Baughn, Aaron Sarver, Tian Xia, Raamesh Deshpande, Aatif Mansoor, Susan A. Walsh, John J. Sunderland, Nathan G. Dolloff, Michael A. Linden, Fenghuang Zhan, Siegfried Janz, Chad L. Myers and Brian G. Van Ness

Mol Cancer Ther June 1 2013 12 (6) 1140-1150; DOI:10.1158/1535-7163.MCT-12-1151

Main menu

User menu

Search

Table of Contents

Highlights

Reviews

Chemical Therapeutics

Large Molecule Therapeutics

Cancer Therapeutics Insights

Companion Diagnostics & Cancer Biomarkers

Tools and Technologies

Issue Highlights

Jump to

Articles

Info for

About MCT